Zukünftige Therapiekonzepte am Beispiel des Multiplen Myeloms

Bei vielen hämatologischen Erkrankungen sind heute v. a. die Patienten problematisch, bei denen die Krankheit auf die unterschiedlichen Substanzklassen nicht mehr anspricht. Dieser Beitrag beleuchtet neue Behandlungsmöglichkeiten, welche die Therapie grundlegend verändern werden, am Beispiel des Multiplen Myeloms.

Publication History

Article published online:
01 December 2020

• Literatur

• 1 Dimopoulos MA, Dytfeld D, Grosicki S. et al Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med 2018; 379: 1811-1822
• 2 Richardson PG, Oriol A, Beksac M. et al Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20: 781-794
• 3 Attal M, Richardson PG, Rajkumar SV. et al Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 2019; 394: 2096-2107
• 4 Dimopoulos M, Quach H, Mateos MV. et al Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 2020; 396: 186-197
• 5 Moreau P, Dimopoulos MA, Mikhael J. et al Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (IKEMA): interim analysis of a phase 3, randomized, open-label study. EHA 2020; abstract LBA2603
• 6 Gandhi UH, Cornell RF, Lakshman A. et al Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 2019; 33: 2266-2275
• 7 Lonial S, Lee HC, Badros A. et al Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020; 21: 207-221
• 8 Raje N, Berdeja J, Lin Y. et al Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med 2019; 380: 1726-1737
• 9 San Miguel J, Shah N, Oriol A. et al Idecaptagene vecleucel (Ide-cel; bb2121), a BCMA-targeted CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: initial KarMMa results. EHA 2020; abstract S209
• 10 Berdeja JG, Madduri D, Usmani SZ. et al Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma. ASCO 2020; abstract 8505
• 11 Lejeune M, Köse MC, Duray E. et al Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Front Immunol 2020; 11: 762
• 12 Costa LJ, Wong SW, Bermudez A. et al Interim results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) 2 + 1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed/refractory multiple myeloma (rrMM). EHA 2020; abstract S205
• 13 Mateos MV, Usmani SZ, Nahi H. et al A phase 1 study of teclistamab, a humanized B-cell maturation antigen (BCMA) × CD3 bispecific antibody, for the treatment of relapsed and/or refractory multiple myeloma (rrMM). EHA 2020; abstract S206
• 14 Pont M, Hill T, Cole GO. et al γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood 2019; 134: 1585-1597